Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd ... Pharmaceutical Processing 13,14 Inotuzumab is currently being evaluated in a Phase 3 study in combination with rituximab in patients with relapsed or refractory CD22-positive aggressive NHL who are not candidates for intensive high-dose chemotherapy. 7 For the first time, ... |
